COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 2 for:    suvn-502
Previous Study | Return to List | Next Study

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease (SUVN-502)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03564964
Expanded Access Status : Available
First Posted : June 21, 2018
Last Update Posted : September 24, 2019
Information provided by (Responsible Party):
Suven Life Sciences Limited

Brief Summary:

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria.

Subjects will not be evaluated for efficacy and safety during the expanded access.

Condition or disease Intervention/treatment
Alzheimer Disease Dementia Cognition Disorders Drug: SUVN-502

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Intermediate-size Population
Official Title: An Intermediate-Size, Expanded Access to SUVN-502 for the Treatment of Subjects With Alzheimer's Disease Who Have Completed the CTP2S1502HT6 Study

Intervention Details:
  • Drug: SUVN-502

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Subjects who have completed the 30 week treatment period of study CTP2S1502HT6 as planned and wish to continue treatment with SUVN-502.
  • Subject (or subject's legally acceptable representative) and caregiver must sign the Informed Consent Form (ICF) to participate in the study.

Exclusion Criteria:

  • Has participated or is participating in any other clinical (investigational) study after completion of CTP2S1502HT6 study.
  • Is treated or likely to require treatment during the study with any medication prohibited by this expanded access program.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03564964

Layout table for location contacts
Contact: Ramakrishna Nirogi +91 9392483002

Sponsors and Collaborators
Suven Life Sciences Limited
Layout table for additonal information
Responsible Party: Suven Life Sciences Limited Identifier: NCT03564964    
Other Study ID Numbers: EAP1502HT6
First Posted: June 21, 2018    Key Record Dates
Last Update Posted: September 24, 2019
Last Verified: September 2019
Keywords provided by Suven Life Sciences Limited:
Expanded Access
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognition Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs